Opinion|Videos|August 14, 2024
Efficacy and Safety of Imetelstat in ESA- ineligible patients
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series
- Please discuss the efficacy and safety findings from IMerge in patients for patients who have sermon EPO levels >500m U/L (ESA ineligible):
- IMerge (Platzbecker et al. Lancet 2024) (Santini et al. EHA 2024, Abstr. S184)
- MEDALIST (Fenaux et al. NEJM 2020) (Santini et al. ASH 2023, Abstr. 915)
Advertisement
Related to this article
Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
3
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5